Wordt geladen...
Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission....
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3514089/ https://ncbi.nlm.nih.gov/pubmed/23210842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2162-3619-1-17 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|